MAFLD comorbid type 2 diabetes
Conditions
Interventions
MAFLD + Type 2 Diabetes Group:None
Sponsors
The First Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Normal metabolic group: No previous history of hypertension, dyslipidemia, coronary heart disease or cerebral infarction. There is no previous history of diabetes and no family history of diabetes. The body mass index (BMI) ranges from 18.5kg/m ² to 23.9 kg/m ². Systolic blood pressure (SBP) = 11.1mmol/L (200mg/dl), or fasting plasma glucose >= 7.0mmol/L (126mg/dl) Or, if the 2-hour blood glucose level in the oral glucose tolerance test is greater than or equal to 11.1mmol/L (200mg/dl), diabetes can be diagnosed if any one of the above three conditions is met. However, if there are no typical symptoms of diabetes, a repeat measurement on another day is required for confirmation before a diagnosis can be made.
Exclusion criteria
Exclusion criteria: 1. Normal metabolism group: Drugs that may affect glucose metabolism, such as glucocorticoids, thyroid hormones, thiazide drugs, etc., were used within one month before the investigation and during the investigation. History of malignant tumors. A history of severe mental disorders. Parenteral nutrition history within one month before the investigation and during the investigation. Unable to cooperate with research investigations. No informed consent form was signed. 2.MAFLD group: History of heavy alcohol consumption; Specific diseases that can lead to fatty liver, such as autoimmune liver disease, viral hepatitis, drug-induced liver disease, total parenteral nutrition, and hepatolenticular degeneration; Endocrine diseases, such as hyperthyroidism or hypothyroidism, Cushing's syndrome, acromegaly, etc. Liver fibrosis, malignant tumors, liver, kidney and heart insufficiency, and other progressive fatal diseases; Use any drugs that affect insulin secretion and insulin sensitivity. 3.Type 2 diabetes group: Patients who are unwilling or unable to sign the informed consent form; Participating in other clinical research projects is defined as having signed the informed consent form. Fasting blood glucose was greater than 16.7mmol/L or glycated hemoglobin was greater than 11% during screening; Pregnant women or women planning to become pregnant; Type 1 diabetes, special types of diabetes; Heart failure patients with NYHA grade III-IV cardiac function; Patients with an estimated glomerular filtration rate (eGFR) of less than 30mL/min/1.73m^2; Patients with severe systemic infections; Patients diagnosed with malignant tumors; Patients with severe mental illness who are unable to cooperate; There is a history of long-term drug dependence or alcohol dependence in the past.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Through multi-omics exploration of the occurrence and development mechanism of NAFLD, a non-invasive diagnostic model was constructed to identify NAFLD at an early stage and search for new therapeutic targets; | — |
Secondary
| Measure | Time frame |
|---|---|
| Observe the structure of patients and intestinal microecological flora during the development of MAFLD;Dynamic changes in proteins and signaling pathways; | — |
Countries
China
Contacts
Public ContactJiang Yan
The First Affiliated Hospital of Kunming Medical University
Outcome results
None listed